Monday, February 14, 2022

February 14, 2022 at 04:07PM Atgam

Product approval information is indicated for:
o The management of allograft rejection in renal transplant patients.
o The treatment of moderate to severe aplastic anemia in patients who are unsuitable for bone marrow transplantation.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/s5kBcIE

No comments:

Post a Comment